Display options
Share it on

Beilstein J Org Chem. 2012;8:2091-9. doi: 10.3762/bjoc.8.235. Epub 2012 Nov 29.

Cyclodextrin-based nanosponges as drug carriers.

Beilstein journal of organic chemistry

Francesco Trotta, Marco Zanetti, Roberta Cavalli

Affiliations

  1. Dipartimento di Chimica. University of Torino, Via Pietro Giuria 7 10125 Torino, Italy.

PMID: 23243470 PMCID: PMC3520565 DOI: 10.3762/bjoc.8.235

Abstract

Cyclodextrin-based nanosponges, which are proposed as a new nanosized delivery system, are innovative cross-linked cyclodextrin polymers nanostructured within a three-dimensional network. This type of cyclodextrin polymer can form porous insoluble nanoparticles with a crystalline or amorphous structure and spherical shape or swelling properties. The polarity and dimension of the polymer mesh can be easily tuned by varying the type of cross-linker and degree of cross-linking. Nanosponge functionalisation for site-specific targeting can be achieved by conjugating various ligands on their surface. They are a safe and biodegradable material with negligible toxicity on cell cultures and are well-tolerated after injection in mice. Cyclodextrin-based nanosponges can form complexes with different types of lipophilic or hydrophilic molecules. The release of the entrapped molecules can be varied by modifying the structure to achieve prolonged release kinetics or a faster release. The nanosponges could be used to improve the aqueous solubility of poorly water-soluble molecules, protect degradable substances, obtain sustained delivery systems or design innovative drug carriers for nanomedicine.

Keywords: controlled release; cross-linked polymers; cyclodextrin; drug delivery; nanosponges

References

  1. AAPS PharmSciTech. 2011 Mar;12(1):279-86 - PubMed
  2. Pharm Dev Technol. 2013 May-Jun;18(3):619-25 - PubMed
  3. Beilstein J Org Chem. 2012;8:1305-11 - PubMed
  4. Biomacromolecules. 2009 Dec 14;10(12):3157-75 - PubMed
  5. Int J Pharm. 2010 Dec 15;402(1-2):254-7 - PubMed
  6. Drug Deliv. 2010 Aug;17(6):419-25 - PubMed
  7. Dalton Trans. 2009 Sep 7;(33):6507-12 - PubMed
  8. Adv Drug Deliv Rev. 1999 Mar 1;36(1):29-40 - PubMed
  9. J Phys Chem B. 2012 May 3;116(17):5323-7 - PubMed
  10. Drug Dev Ind Pharm. 2013 Sep;39(9):1263-72 - PubMed
  11. Int J Pharm. 2002 Jan 31;232(1-2):175-81 - PubMed
  12. Int J Pharm. 2000 Dec 15;211(1-2):19-27 - PubMed
  13. Eur J Pharm Sci. 2012 Nov 20;47(4):686-94 - PubMed
  14. Methods Enzymol. 2012;509:1-19 - PubMed
  15. Int J Pharm. 2012 May 30;428(1-2):152-63 - PubMed
  16. Pharm Res. 1995 Mar;12(3):413-20 - PubMed
  17. Eur J Cancer. 2001 Sep;37(13):1590-8 - PubMed
  18. Int J Pharm. 2013 Aug 30;453(1):167-80 - PubMed
  19. Eur J Pharm Biopharm. 2010 Feb;74(2):193-201 - PubMed

Publication Types